{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:21:55Z","timestamp":1740126115981,"version":"3.37.3"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1111\/bjd.16226","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T09:31:20Z","timestamp":1518600680000},"page":"320-321","source":"Crossref","is-referenced-by-count":0,"title":["Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid"],"prefix":"10.1093","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8098-9220","authenticated-orcid":false,"given":"T.","family":"Sach","sequence":"first","affiliation":[{"name":"Health Economics Group; Norwich Medical School; University of East Anglia; Norwich NR4 7TJ U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"10.1111\/bjd.16226-BIB0001|bjd16226-cit-0001","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjd.16006","article-title":"Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial","volume":"178","author":"Mason","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16226-BIB0002|bjd16226-cit-0002","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"UK Dermatology Clinical Trials Network BLISTER Study Group. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"10.1111\/bjd.16226-BIB0003|bjd16226-cit-0003","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","article-title":"CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1111\/bjd.16226-BIB0004|bjd16226-cit-0004","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0167-6296(98)00039-3","article-title":"The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies","volume":"18","author":"Claxton","year":"1999","journal-title":"J Health Econ"},{"key":"10.1111\/bjd.16226-BIB0005|bjd16226-cit-0005","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/1745-6215-14-421","article-title":"Trial-based clinical and economic analyses: the unhelpful quest for conformity","volume":"14","author":"Whitehurst","year":"2013","journal-title":"Trials"},{"key":"10.1111\/bjd.16226-BIB0006|bjd16226-cit-0006","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1524-4733.2007.00245.x","article-title":"Practical guidelines for economic evaluations alongside equivalence trials","volume":"11","author":"Bosmans","year":"2008","journal-title":"Value Health"},{"key":"10.1111\/bjd.16226-BIB0007|bjd16226-cit-0007","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.cct.2011.07.007","article-title":"Power and sample size for cost-effectiveness analysis: fFN neonatal screening","volume":"32","author":"Boyd","year":"2011","journal-title":"Contemp Clin Trials"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16226","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16226\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:38:24Z","timestamp":1676381904000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/178\/2\/320\/6732178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.16226","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"type":"print","value":"0007-0963"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}